CCR2 and obesity disorder: Tamura et al. [126] investigated the effects of propagermanium (a CCR2 inhibitor) on obesity and type 2 diabetes by administering a standard diet supplemented with propagermanium to 6-week-old db/db mice for 12 weeks.